Posted by Michael Wonder on 01 Nov 2022
Dyne Therapeutics receives FDA fast track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy
31 October 2022 - Company anticipates reporting data from global, multiple ascending dose DELIVER clinical trial in the second half of 2023.
Dyne Therapeutics today announced that the US FDA has granted fast track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.
